NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
pharma Pool Dr. John ORLOFF Merck Serono Names Head of Global Clinical Development Merck Serono has named John Orloff, M.D., as head of global clinical development. Dr. Orloff leads the design and execution of Merck Serono’s global clinical development programs and projects, driving quality execution of the projects after proof-of-concept (POC). He also oversees pipeline management and development, working collaboratively with the research teams, commercial partners and medical affairs to drive the efficient development of Merck’s portfolio. Dr. Orloff comes to Merck Serono from Novartis Pharma AG, where he most recently served as senior VP and chief medical officer. Dr. Orloff received his medical degree from the University of Vermont College of Medicine. He completed his residency at the University of Pittsburgh. Mark TIMNEY Purdue Pharma Names President and CEO Mark Timney has been named president and CEO of Purdue Pharma. Mr. Timney brings more than 20 years of pharmaceutical sales and marketing experience to Purdue, including success in designing and executing strategies to achieve market leadership. Before joining Purdue, he was president of Merck US, where he managed sales and marketing, managed markets, and payers. Eddie WILLIAMS Novo Nordisk Promotes Diabetes Expert Novo Nordisk, a global healthcare company focused on diabetes care, has promoted Eddie Williams to senior VP of biopharmaceuticals from corporate VP of biopharmaceuticals. He joined Novo Nordisk in 2006 and has led the sales and marketing, business development, and new product commercialization functions for the company’s growing U.S. biopharmaceuticals business, which develops medicines for people with hemophilia, as well as various types of hormone deficiencies. Biopharma Pool Lisa Buffington Allene Diaz Dr. Alexander Kuta Michael Ruggiero Gary Zieziula EMD Serono Strengthens Leadership With New Appointments EMD Serono, a subsidiary of Merck KGaA, announced the appointments of Lisa Buffington as VP of U.S. communications; Allene Diaz as senior VP of managed markets; Alexander Kuta,?Ph.D., as VP and head of U.S. regulatory affairs; and Michael Ruggiero as VP of U.S. government affairs and policy; and Gary Zieziula as chief commercial officer. Ms. Buffington is responsible for driving and executing all aspects of the company’s communications strategy, including external and employee communications, media relations, corporate reputation, product communications, community relations, as well as meetings and events. She brings almost 20 years of industry and communications experience to EMD Serono, most recently serving as VP of corporate communications at Ironwood Pharmaceuticals. Ms. Diaz is responsible for developing and executing managed markets marketing, sales, and contracting strategies and tactics to ensure optimal market access and pull through for EMD Serono products. She is also responsible for developing and executing specialty pharmacy patient adherence and retention strategies and tactics. Ms. Diaz brings more than 25 years of both U.S.-based and international industry experience to her new role with the organization, most recently serving as EMD Serono’s senior VP, head of U.S. oncology. Dr. Kuta is responsible for driving the strategic direction of EMD Serono’s regulatory efforts with the FDA, overseeing regulatory submissions in the United States and strengthening interactions with the FDA. He joins EMD Serono with almost 25 years of regulatory experience, most recently from Lantheus Medical Imaging, where he was VP of global regulatory affairs. Mr. Ruggiero is responsible for federal and state legislative, policy, political, and advocacy strategy and execution for EMD Serono’s business. He also serves as a member of the global government affairs and policy (GA&P) leadership team. Mr. Ruggiero most recently served as VP of government strategy for Astellas Pharma US. Mr. Zieziula is responsible for maximizing the growth of the U.S. organization by driving the performance of its franchises. He has more than 30 years of experience in the pharmaceutical industry and in specialty care, most recently serving as an independent consultant focused on opportunity assessments for development-stage products, and mergers and acquisitions. Peter GREENLEAF Sucampo Names CEO Sucampo Pharmaceuticals has named Peter Greenleaf CEO. Mr. Greenleaf brings to Sucampo more than 20 years of experience in commercialization and drug development in the biopharmaceutical industry. Most recently, he served as president and CEO of Histogenics. Joseph OLIVETO Chelsea Therapeutics Names President and CEO Chelsea Therapeutics has named Joseph Oliveto president and CEO, an interim role he has held since July 2012. Mr. Oliveto joined Chelsea Therapeutics in June 2008, as VP of operations. Prior to joining Chelsea, Mr. Oliveto held progressively senior operating roles at Roche. Dr. Janice SMIELL Alliqua Names Chief Medical Officer Alliqua, a biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies, has appointed Janice Smiell, M.D. as chief medical officer, a newly created position. Dr. Smiell has more than two decades of experience in clinical trial design, clinical development and planning, and clinical regulatory submissions. In practice as a general surgeon, she has specialized in wound healing, wound care, and trauma. Most recently, Dr. Smiell was an independent consultant in drug, device, tissue and cells clinical development planning, as well as medical monitoring and management. CRO Pool Dr. Beatrice SETNIK Dr. Susan TIMONEY Dr. Asli TURKES INC Research Strengthens Management Team INC Research, a therapeutically focused global clinical research organization, has appointed Beatrice Setnik, Ph.D., as VP, clinical pharmacology. Dr. Setnik is supporting INC Research’s early phase business unit, providing scientific direction on matters related to abuse liability. Dr. Setnik joins INC Research from Pfizer, most recently serving as senior director, medical development-neuroscience, where she led clinical development, including abuse potential evaluation of several opioid formulations. In other news, Susan Timoney, Ph.D., has joined the company as executive director, clinical development, oncology, and Asli Turkes, Ph.D., has been named VP, clinical development, oncology. Dr. Lynn OKAMOTO inVentiv Health Clinical Appoints Executive VP, Late-Stage Business Unit inVentiv Health Clinical, a global supplier of drug development services, has named Lynn Okamoto, Pharm.D., executive VP of the late-stage business unit, which works seamlessly with inVentiv experts in study design and implementation, market access, reimbursement, stakeholder relations, and scientific communications to anticipate the questions that will be asked in the marketplace and assure clients are armed with effective answers. Dr. Okamoto most recently served as senior VP and senior research scientist of health economics and epidemiology at Evidera. Agency Pool German DZIEBEL Marci Piasecki GSW Makes Several Appointments GSW, an inVentiv Health company, has appointed German Dziebel as executive VP, director of strategy, for the agency’s Columbus office. In this role, Mr. Dziebel will apply his expertise as an anthropologist and expert in human behavior, culture, and brand strategy to design custom marketing solutions for new and existing clients. He is charged with directing the expansion of GSW’s Speak People philosophy, the agency’s proprietary approach to enriching the conversation between people and healthcare. In other news, Marci Piasecki has been appointed president of GSW East to oversee the agency’s New York City and Newtown, Pa., offices. She also serves as managing director of inVentiv Health Communications (iHC) Media 360 and inVentiv Creative Studios (iCS) to lead the division’s strategic media planning, production and studio capabilities. Ms. Piasecki joins GSW/iHC from McCann Health North America where she was responsible for leading five healthcare communications companies. Dan HASSEN Colleen HINDSLEY Maureen REGAN McCann Makes Major Moves Dan Hassan has been promoted to chief creative officer at McCann RCW. Mr. Hassan has been the executive creative director at the agency for the last 10 years. Colleen Hindsley has been promoted to director of client services. Ms. Hindsley has been a senior account leader with the agency since 2002. The agency’s Founder and Chairwoman Maureen Regan is transitioning her day-to day responsibilities at McCann RCW and taking on a role working closely on business development with McCann RCW and McCann Health CEO John Cahill. Ms. Regan is a founding partner of McCann RCW and has been a very influential member of the McCann Health team. Katie PIETTE Ogilvy CommonHealth Names Director of Brand Management Ogilvy CommonHealth Worldwide, the health behavior experts of Ogilvy & Mather, has promoted Katie Piette to director of global brand management (GBM). Ms. Piette has more than 18 years of international client management experience with a strong focus on healthcare communications. Ms. Piette joined Ogilvy & Mather in 2000 to work on the launch of the IBM global strategic alliances and in 2003 she transitioned to OgilvyOne, Ogilvy’s customer engagement agency. In 2006, she joined Ogilvy CommonHealth to help develop the international client base in Europe. Ms. Piette’s new responsibilities include leading the GBM team across Ogilvy CommonHealth Worldwide’s various disciplines. She is also charged with developing and maintaining the agency’s international client relationships. Service Pool Dr. Michael ALLEN Kris KUHNER ProPhase Announces Hires ProPhase, a specialty services organization focusing on applied measurement in CNS — psychiatry, neurology, sleep and pain disorders, and rare/orphan diseases — for clinical trial activities, has hired Michael Allen, M.D., as VP of medical education, and Kris Kuhner, as VP of business development. Dr. Allen brings deep clinical experience, a distinguished academic career, and leadership roles in several associations aimed at improving treatment paradigms for psychiatry patients. Most recently at the University of Colorado, he served as the director of psychiatry for the University Hospital and as professor of psychiatry and emergency medicine. Mr. Kuhner brings 14 years of experience in pharmaceutical and clinical research. His diversity of experience spans clinical operations and commercial leadership roles, across CNS, oncology, and cardiovascular programs. Mr. Kuhner worked for AstraZeneca, Wyeth, and ICON. Both Dr. Allen and Mr. Kuhner will build on ProPhase’s recent commercial successes in partnering to deliver highly customized solutions that support clinical trials in more than 60 countries, in all phases, across 18 primary indications. Biopharma Pool Paul Carter Dr. John McHutchison Gilead Announces Executive Promotions Gilead has promoted Paul Carter to executive VP with responsibility for its worldwide commercial organization. He was formerly senior VP, international commercial operations. John McHutchison, M.D., formerly senior VP, liver disease therapeutics, has been promoted to executive VP and will assume additional responsibility for clinical development programs in the areas of oncology, respiratory diseases, and inflammation. Dr. Seymour FEIN Ventria Bioscience Appoints Chief Medical Officer Ventria Bioscience has appointed Seymour Fein, M.D., as its new chief medical officer. Dr. Fein is responsible for the company’s clinical development and medical affairs functions. Dr. Richard WOOSTER Blend Therapeutics Appoints Chief Scientific Officer Blend Therapeutics, a biopharma company discovering new classes of medicines to treat cancer, has appointed pharmaceutical industry veteran Richard Wooster, Ph.D., as chief scientific officer. Dr. Wooster is responsible for leading the company’s research and development strategy and clinical operations as its lead drug candidates focused on oncology advance toward clinical development. Before joining Blend, Dr. Wooster was VP and head of the cancer metabolism discovery performance unit in oncology at GlaxoSmithKline. Biotech Pool Rick BURCH Innovative Med Concept Names President Rick Burch joins Innovative Med Concepts, a biotech company, following his most recent role as VP and general manager of the CNS business unit for UCB. Innovative Med Concepts is developing novel treatments for fibromyalgia, irritable bowel syndrome and a number of other related conditions. Eric GUEMPEL ImmunoGen Appoints VP, Product Strategy and Program Management ImmunoGen, a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, has appointed Eric Guempel as VP of product strategy and program management. Mr. Guempel brings to ImmunoGen more than 30 years of experience in the healthcare industry, including extensive experience in commercial functions related to the strategic development of novel oncology products. Dr. Timothy Ocain Enanta Appoints Senior VP, New Product Strategy and Development Enanta Pharmaceuticals has appointed Timothy Ocain, Ph.D., as senior VP, new product strategy and development. Dr. Ocain has more than 25 years of experience working in the pharmaceutical and biotechnology environment with experience in medicinal chemistry, pharmacology, biochemistry, program management, and preclinical and early development across multiple therapeutic areas. He is co-author on more than 30 publications and co-inventor on 17 patents. Specialty Pool Gregg RAYBUCK K-V Pharmaceutical Appoints Healthcare Veteran, to Lead New Maternal Health Division K-V Pharmaceutical has appointed Gregg Raybuck, a healthcare veteran with experience in women’s and children’s health, president of its newly created Maternal Health Division, which focuses on marketing and developing FDA-approved products that address pregnancy management. Service Pool Gaye CORBIN Research Across America Expands Research Across America (RAA), a wholly owned network of clinical investigative sites, has named Gaye Corbin to senior director, business development. Technology Pool Laurence BURKE Exco InTouch Names VP Exco InTouch, a provider of patient engagement and data capture solutions, has appointed Laurence Burke as VP of operations. Chief among his responsibilities is ensuring that processes are as streamlined and efficient as possible. He has responsibility for operations in servicing customers in the clinical, late phase, and mHealth field.